

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Batra et al.

Examiner:  
Not Yet Assigned

Serial No.: Not Yet Assigned

Previous Examiner:  
Sharareh, S.

(Continuation application of  
USSN 09/312,617)

Docket No.: 20243CA

Art Unit: Not yet assigned

Express Mailed: June 29, 2001

Previous Art Unit:

For: "COMPRESSED TABLET FORMULATION"

Box PATENT APPLICATION  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Express Mail Certificate

DATE OF DEPOSIT: JUNE 28, 2001  
EXPRESS MAIL NO. 152316526515  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL, "POST OFFICE TO  
ADDRESSEE" BEFORE 6 P.M. ON THE ABOVE DATE IN  
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER  
FOR PATENTS, WASHINGTON, D.C. 20231.  
RECEIVED  
JULY 1, 2001  
6/28/01

PRELIMINARY AMENDMENT

Sir:

Applicants request entry of this amendment prior to examination of the above-identified application, which is a Rule 53(b) continuation of USSN 09/312,617. Please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please insert the following paragraph on page 1 after the Title:

-- This application is a continuation of US Serial No. 09/312,617, filed January 17, 2001, which is a continued prosecution application under 37 C.F.R. § 1.53(d) of US Serial No. 09/312,617, filed May 17, 1999, now abandoned, which claims the benefit of US Provisional Application No. 60/086,921, filed May 27, 1998.--

Replace the fourth paragraph on page 7 with the following paragraph:

-- The formulation also is bioequivalent to a capsule with a smaller dose (200 mg), and more bioavailable than other tablet compositions. The advantages over the capsule include robust processing and sorting steps, smaller size with a larger dose, and market preference. The